Sinteza i vrednovanje analgetskog, protuupalnog i ulcerogenog djelovanja nekih triazolo- i 2-pirazolil-pirido[2,3-d]-pirimidina by HEND N. HAFEZ et al.
It is already known that some pyrimido[4,5-b]quinolin-4-one derivatives display an
interesting analgesic action in the writhing syndrome and hotplate tests and are not to-
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vatives were prepared in order to obtain new compounds
with potential anti-inflammatory and analgesic activity and
low ulcerogenic effect. The compounds possessing potent
anti-inflammatory activity were further tested for their an-








-pyrido[2,3-d]pyrimidin-4(H)-one (10a) and 3-thioxo-6-(4-
-aryl)-9-(4-arylmethylene)-cyclopenta[5,6]pyrido[2,3-d]-
[1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (13) showed sig-
nificant analgesic effects. Compound 2-(3-amino-5-hydro-
xypyrazol-1-yl)-5-(4-aryl)-8-(4-arylmethylene)-cyclopenta
[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (10a) was evaluated
as the lead compound having higher anti-inflammatory
activity (82.8%) than ibuprofen (79.5%) and lower ulce-
rogenic effect.
Keywords: pyrido[2,3-d]pyrimidines, [1,2,4]triazole anella-
tion, anti-inflammatory, analgesic activity
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xic (1). Also, pyrido[2,3-d]pyrimidin-7(8H)-ones have attracted interest of pharmaceuti-
cal companies due to the wide range of biological activities associated with this scaffold.
Thus, a search revealed that more than 3000 structures of type A (Fig. 1) have been de-
scribed; they show biological activities ranging from kinase inhibition (platelet-derived
growth factor, PDGFr, fibroblast growth factor, FGFr, and epidermal growth factor, EGFr)
(2), CSP/p38 kinase inhibition (3), Src tyrosine kinase inhibition (4, 5), cdk4 inhibition
(6), p38 MAP kinase inhibition (7), cyclin dependent kinase inhibition (8, 9) telomerase
inhibition (10) for the treatment of arthritis, Crohn’s disease, irritable bowel syndrome,
adult respiratory distress syndrome, chronic obstructive pulmonary disease, or Alzhei-
mer’s disease (11).
Moreover, due to their biological properties, which mainly depend on the nature
and position of substituents, pyridopyrimidine derivatives are pharmaceutically active
(12–17), including bactericidal (13), anticancer (14) and anti-inflammatory (17) activity.
This prompted us to synthesize and identify new compounds derived from pyrido-
[2,3-d]pyrimidin-4-ones and to screen them for analgesic and anti-inflammatory activi-
ties.
EXPERIMENTAL
All melting points were measured using an Electrothermal IA 9100 apparatus (Shi-
madzu, Japan) (Table I). 1H NMR (Table II) and 13C NMR spectra (Table III) were re-
corded on JEOL EX-270 and JEOL ECA-500 (Jeol, Japan) and chemical shifts were ex-
pressed as d values against Si(CH3)4 as internal standard. IR spectra were recorded as
KBr pellets on a Perkin-Elmer 1430 spectrometer (USA). Mass spectra (Table II) were re-
corded on a Hewlett-Packard-5988A GC/MS (USA) at ionization potential of 70 eV.
Synthesis of 5-aryl-8-arylmethylene-7,8-dihydro-2-thioxo-6H-cyclopenta[5,6]pyrido-[2,3-d]-pyri-
midin-4(H)-ones (1a-c)
The title compounds were prepared according to El-Gazzar et al. (18).
Synthesis of 5-aryl-8-arylmethylene-2-hydrazino-7,8-dihydro-6H-cyclopentena-[5,6]-pyrido-
[2,3-d]pyrimidin-4(H)-one (2a-c). General procedure
A suspension of compound 1a-c (0.01 mol) in hydrazine hydrate (99–100 %) (25 mL)
was stirred under reflux. The insoluble solid went into solution within 10 minutes with
copious evolution of mercaptan to form a clear solution. After 30 minutes, heating was
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continued for 8 h and the reaction mixture was allowed to cool to room temperature.
The solid separated was filtered off, washed with ethanol and dried to produce 2a-c.
5-Phenyl-8-phenylmethylene-2-hydrazino-7,8-dihydro-6H-cyclopentena[5,6]pyrido-[2,3-d]
pyrimidin-4(H)-one (2a). – Compound 2a was obtained from 1a as a yellow powder
which was crystallized from DMF.
5-(4-Chlorophenyl)-8-(4-chlorophenylmethylene)-2-hydrazino-7,8-dihydro-6H-cyclo-penta[5,6]-
pyrido[2,3-d]pyrimidin-4(H)-one (2b). – Compound 2b was obtained from 1b as a yellow
powder which crystallized from dioxane.
5-(4-Methoxyphenyl)-8-(4-methoxyphenylmethylene)-2-hydrazino-7,8-dihydro-6H-cyclo-
penta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (2c). – Compound 2c was obtained from 1c as
a yellow powder crystallized from ethanol/dioxane (1:1).
Synthesis of 5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-2-acethydrazido-7,8-dihy-
dro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (3)
A solution of compound 2c (0.01 mol) in glacial acetic acid, was refluxed for 3 h. The
reaction mixture was allowed to cool to room temperature and was poured into cold wa-
ter (100 mL). The solid formed was collected by filtration, dried and crystallized from
ethanol (dark yellow powder).
Synthesis of 6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-1,7,8,9-tetrahydrocyclopenta-
[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (4a)
A mixture of 2c (0.01 mol) and formic acid (10 mL) and 2 mL of concentrated hydro-
chloric acid was heated under reflux for 8 h. The reaction mixture was allowed to cool to
room temperature and was poured into water (100 mL). The solid formed was collected




Method A. – A mixture of 2c (0.01 mol) and glacial acetic acid (50 mL) was stirred
under reflux for 10 h (TLC). The reaction mixture was allowed to cool to room tempera-
ture an was then poured into water (100 mL). The solid formed was collected by filtra-
tion, washed with ethanol (20 mL), dried, and crystallized from dioxane as an orange
powder.
Method B. – A mixture of 3 (0.01 mol) and glacial acetic acid (30 mL) was stirred un-
der reflux for 7 h (TLC). The reaction mixture was allowed to cool to room temperature
and was then poured into water (100 mL). The solid formed was collected by filtration,
washed with ethanol (20 mL) and crystallized.
Synthesis of 3-amino-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-1,7,8,9-tetrahydro-
cyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (4c)
A mixture of 2c (0.01 mol) and potassium thiocyanate (0.15 mol) was heated under
reflux in glacial acetic acid (30 mL) for 6 h. The reaction mixture was allowed to cool to
room temperature and was poured into water. The precipitate formed was collected by
filtration, dried and crystallized from ethanol/dioxane (2:1) as a yellow powder.
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Synthesis of 3-aryl-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-1,7,8,9-tetrahydrocy-
clopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (4d-f). General procedure
A mixture of compound 7a-c (0.01 mol), anhydrous sodium acetate (1.64 g, 0.02 mol)
and bromine (1.60 g, 0.01 mol) was stirred under reflux in glacial acetic acid (30 mL) in a
water-bath at 80 °C for 20 h (under TLC control). The reaction mixture was allowed to
cool to room temperature, was poured into water (100 mL) and the solid formed was
collected by filtration and crystallized from appropriate solvent to afford 4d-f.
6-(4-Methoxyphenyl)-9-(4-methoxyphenylmethylene)-3-phenyl-1,7,8,9-tetrahydro-cyclopen -
ta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (4d). – Compound 4d was ob-
tained from 7a, as a yellow powder crystallized from dioxane.
3-(4-Chlorophenyl)-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-1,7,8,9-tetrahydro-
cyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (4e). – Compound 4e was
obtained from 7b as a yellow powder crystallized from dioxane.
3,6-Di-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-1,7,8,9-tetrahydrocyclo-penta[5,6]
pyrido[2,3-d][1,2,4] triazolo[4,3-a]pyrimidin-5(H)-one (4f). – Compound 4f was obtained
from 7c as a yellow powder which was crystallized from DMF.
Synthesis of 6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-8,9-dihydro-7H-cyclopenta-[5,6]py-
rido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (5a,b). General procedure
To a warmed ethanolic sodium ethoxide solution (prepared by dissolving 0.01 mol
of sodium metal in 30 mL ethanol), each of 4a,b (0.01 mol), was added, the heating was
continued for 30 min and the mixture was allowed to cool to room temperature. Then
methyl iodide (0.012 mol) was added. The mixture was stirred under reflux for 3 h, cooled
to room temperature and poured into cold water (100 mL). The solid precipitated was
filtered off, washed with water and dried to produce 5a,b.
1-Methyl-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-8,9-dihydro-7H-cyclopenta-
[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (5a). – Compound 5a was obtai-
ned from 4a (10 mmol) and methyl iodide (0.012 mol) as yellow crystals crystallized from
dioxane.
1,3-Dimethyl-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-8,9-dihydro-7H-cyclo-
penta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (5b). – Compound 5b was ob-
tained from 4b (10 mmol) and methyl iodide (0.012 mol) as a yellow powder, crystal-
lized from dioxane.
Synthesis of 1-amino-2-methyl- or phenyl-6-(4-methoxyphenyl)-9-(4-methoxyphenyl-methylene)-
-8,9-dihydro-7H-cyclopenta[5,6]pyrido[2,3-d]imidazolo[1,2-a]pyrimidin-5(H)-one (6a,b).
General procedure
A mixture of compound 2c (0.01 mol) and chloroacetone or 2-bromoacetophenone
(0.01 mol) was heated under reflux for 12 h in dry xylene (30 mL). The solid that sepa-
rated upon cooling was filtered off and crystallized from appropriate solvent to produce
6a,b.
1-Amino-2-methyl-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-8,9-dihydro-7H-cy-
clopenta[5,6]pyrido[2,3-d]imidazolo[1,2-a]pyrimidin-5(H)-one (6a). – Compound 6a was ob-
tained from compound 2c (0.01 mol) and chloroacetone (0.01 mol) as white crystals crys-
tallized from ethanol.
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1-Amino-2-phenyl-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-8,9-dihydro-7H-cy-
clopenta[5,6]pyrido[2,3-d]imidazolo[1,2-a]pyrimidin-5(H)-one (6b). – Compound 6b was ob-
tained from compound 2c (0.01 mol) and 2-bromoacetophenone (0.01 mol) as a yellow
powder crystallized from ethanol.
Synthesis of 2-arylmethylenehydrazone-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-
-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (7a-c). General procedure
A mixture of 2c (0.01 mol), the appropriate aromatic aldehyde (0.01 mol) and anhy-
drous sodium acetate (0.02 mol) was stirred under reflux in glacial acetic acid (30 mL)
for 30 min. The reaction mixture was allowed to cool to room temperature. The solid
formed was filtered off and crystallized from appropriate solvent to produce 7a-c.
2-Phenylmethylenehydrazone-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-7,8-dihydro-
-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (7a). – Compound 7a was obtained
from compound 2c (0.01 mol) and benzaldehyde (0.01 mol) as pale yellow crystals crys-
tallized from DMF.
2-(4-Chlorophenyl)methylenehydrazone-5-(4-methoxyphenyl)-8-(4-methoxyphenyl-methy-
lene)7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (7b). – Compound 7b
was obtained from compound 2c (0.01 mol) and 4-chlorobenzaldehyde (0.01 mol) as pale
yellow crystals crystallized from DMF.
2-(4-Methoxyphenyl)methylenehydrazone-5-(4-methoxyphenyl)-8-(4-methoxyphenyl-me-
thylene)-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (7c). Compound 7c
was obtained from compound 2c (0.01 mol) and 4-methoxybenzaldehyde (0.01 mol) as a
yellow powder which was crystallized from DMF.
Synthesis of 6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-1,7,8,9-tetrahydro-cyclopenta-
[5,6]pyrido[2,3-d][1,2,3,4]tetrazolo[4,5-a]pyrimidin-5(H)-one (8)
To an ice-cold solution of compound 2c (0.01 mol) in glacial acetic acid (10 mL), a
solution of sodium nitrite (0.15 mol) in a small amount of water was added dropwise in
an ice bath at –5 °C. The reaction mixture was allowed to stand overnight at room tem-
perature and was then poured into water (100 mL). The solid precipitated was filtered
off and crystallized from ethanol as a yellow powder.
Synthesis of 2-amino-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-7,8-dihydro-6H-cyclo-
penta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (9)
To a well stirred solution of compound 8 (0.01 mol) in glacial acetic acid (30 mL), ac-
tivated zinc dust (5.00 g) was added portion-wise at room temperature over a period of
30 min. Stirring was continued for additional 3 h. Thereafter, the reaction mixture was
heated on a water bath (80–90 °C) for 3 h. The reduction progress was monitored by TLC.
After allowing the reaction mixture to cool to room temperature, it was poured into cold
water (100 mL). The insoluble solid which separated was filtered, washed with water
and dried. The crude solid was extracted with hot diethyl ether and the solid obtained
after the removal of ether under reduced pressure was crystallized from ethanol.
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Synthesis of 2-(3-amino-5-hydroxypyrazol-1-yl)-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethy-
lene)-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (10a)
To a warm ethanolic sodium ethoxide solution (prepared by dissolving (0.01 mol)
sodium metal in absolute ethanol (30 mL), compound 2c (0.01 mol) and ethyl cyanoace-
tate (0.01 mol) were added. The mixture was stirred under reflux for 8 h, the reaction
mixture was allowed to cool to room temperature was then poured into cold water (100
mL) and neutralized with acetic acid. The solid product precipitated was filtered off, wa-
shed with water, ethanol, dried and crystallized from dioxane as a pale yellow powder.
Synthesis of 2-(sub-pyrazol-1-yl)-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-7,8-dihydro-
-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (10b,c). General procedure
A mixture of compound 2c (0.01 mol) and b-diketone (0.01 mol) in absolute ethanol
(30 mL) was stirred under reflux for 5 h. The reaction mixture was allowed to cool to 0
°C for 3 h, the precipitate was filtered off, dried and crystallized from an appropriate
solvent to produce 10b,c.
2-(3,5-Dimethyl-pyrazol-1-yl)-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-7,8-dihydro-
6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (10b). – Compound 10b was obtained
from 2c (0.01 mol) with pentan-2,4-dione (0.01 mol) as pale light crystals crystallized from
dioxane.
2-(3,5-Dimethyl-4-chloropyrazol-1-yl)-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethy-
lene)7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (10c). – Compound
10c was obtained from 2c with 3-chloropentan-2,4-dione (0.01 mol) as a light yellow
powder crystallized from ethanol.
Synthesis of 2-[ethyl-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-7,8-dihydro-6Hcy-
clopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one acetate hydrazone (11)
A mixture of compound 2c (0.01 mol) and ethyl acetoacetate (0.01 mol) was refluxed
in absolute ethanol (30 mL) for 6 h. The reaction mixture was allowed to cool to room
temperature and the solid precipitate produced was filtered off and crystallized from eth-
anol as a pale brown powder.
Synthesis of 5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-2-(3-methyl-4H-pyrazol-5-
-one-1-yl)-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (12)
Method A. – A solution of compound 2c (0.01 mol) and ethyl acetoacetate (0.01 mol)
in sodium ethoxide solution (prepared by dissolving 0.01 mol of sodium metal in 30 mL
absolute) ethanol was heated under reflux with stirring for 6 h. The reaction mixture was
allowed to cool and was poured into cold water (100 mL) and neutralized by acetic acid,
whereby a solid was precipitated, filtered off and crystallized from ethanol to produce
12 as a yellow powder in 65% yield (m.p. 257–259 °C, dec.).
Method B. – A solution of compound 11 (0.01 mol) was heated under reflux with so-
dium ethoxide solution (prepared by dissolving 0.01 mol of sodium metal in 30 mL ab-
solute ethanol) for 3 h. The reaction mixture was allowed to cool, was poured into water
(100 mL) and neutralized by acetic acid; the precipitate formed was filtered off and crys-
tallized from ethanol.
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Synthesis of 3-thioxo-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-1,2,8,9-tetrahydro-
-7H-cyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (13)
To a warmed ethanolic sodium hydroxide solution prepared by dissolving 0.01 mol
of sodium hydroxide in 50 mL ethanol, compound 2c (0.01 mol) and excess carbon di-
sulphide (10 mL) were added. The mixture was heated on a water-bath at 80 °C under
reflux for 12 h, was then allowed to cool to room temperature, poured onto water (100
mL), neutralized by dilute acetic acid and the formed precipitate was filtered off and
dried. The product was crystallized from ethanol as a yellow powder.
Pharmacological screening
Animals. – Adult male Sprague-Dawley rats, weighing 150–200 g, were used for
anti-inflammatory and ulcerogenic activity testing, and Swiss albino mice of both sex,
weighing 25–30 g, were used for analgesic activity testing. International principles and
local regulations concerning the care and use of laboratory animals were observed (19).
The animals had free access to standard commercial diet and water ad libitum and were
kept in rooms maintained at 22 ± 1 °C with a 12 h light dark cycle. The experimental pro-
tocol was approved by the Animal Ethics Committee of the National Research Center,
Cairo, Egypt.
Anti-inflammatory assay. – The compounds synthesized were evaluated for their anti-
-inflammatory activity using the carrageenean induced hind paw edema method (20). The
animals were randomly allocated to groups of six animals each and were fasted for 24 h
before the experiment, with free access to water. Control group received only 0.5% (m/V)
carboxymethyl cellulose solution. Standard drug ibuprofen was administrated orally at a 30
mg kg–1 dose. Carrageenean solution in saline (1%, 0.1 mL) was injected subcutaneously
into the sub-plantar region of the left hind paw of each rat, one hour after the adminis-
tration of the test compounds or standard drug (30 mg kg–1). The left hind paw volume
was measured before and after 3 and 4 h of carrageenean treatment by means of a ple-
thysmometer. The percent edema inhibition was calculated from the mean effect in the
control and treated animals. Each value represents the mean ± SEM relative to the stan-
dard and data were analyzed by ANOVA followed by Dunnett’s test.
Analgesic assay. – Analgesic activity was evaluated by the tail immersion method
(21). Swiss albino mice allocated to different groups consisting of six animals each were
used for the experiment. Analgesic activity was evaluated after oral administration of
the test compounds at a dose of 30 mg kg–1 of ibuprofen and the test compounds. Test
compounds and the standard drug were administered orally as a suspension in carbo-
xylmethyl cellulose solution in water (0.5%, m/V). The analgesic activity was assessed
before and after 4 h following administration of test compounds and standard drug. The
lower 5-cm portion of the tail was gently immersed into thermostatically controlled wa-
ter at 55 ± 0.5 °C. The time in seconds for tail withdrawal from water was taken to be the
reaction time with a cut off time of immersion, set at 100 seconds for both control as well
as treated groups of animals.
Ulcerogenicity. – Acute ulcerogenicity was determined according to the method of
Cioli et al. (22). The animals were allocated to different groups consisting of six animals
each. Ulcerogenic activity was evaluated after oral administration of the test compounds
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at a dose of 30 mg kg–1. Control group received only 0.5% (m/V) carboxymethyl cellu-
lose solution. After the drug treatment, the rats were fed normal diet for 17 h and were
then sacrificed. The stomach was removed and opened along the greater curvature, wa-
shed with distilled water and cleaned gently by dipping in normal saline. The mucosal
damage was examined by means of a magnifying glass. Mucosal damage was assessed
for each stomach according to the following scoring system: 0.5: redness, 1.0: spot ulcers,
1.5: hemorrhagic streaks, 2.0: 3  ulcers  5, 3.0: ulcers > 5. The mean score of each trea-
ted group minus the mean score of the control group was regarded as the severity index
of gastric mucosal damage.
RESULTS AND DISCUSSION
5-Aryl-8-arylmethylene-7,8-dihydro-2-thioxo-6H-cyclopenta[5,6]pyrido[2,3-d]-pyri-
midin-4(H)-ones (1a-c) were synthesized previously (18). Beside the correct values in el-
emental analyses and spectral data, structures were established chemically. Upon treat-
ment with hydrazine hydrate (Scheme 1), thay gave 5-aryl-8-arylmethylene-2-hydra-
zino-7,8-dihydro-6H-cyclopenta[5,6]pyrido-[2,3-d] pyrimidin-4(H)-ones (2a-c), with the
evolution of mercaptan.
Compound 2c could be considered as a starting material for the synthesis of new
polynuclear heterocycles such as azolopyridopyrimidines, as well as the synthesis of
some pyrazolopyridopyrimidine derivatives. Thus, heating compound 2c with aliphatic
acids, namely, formic and acetic acid, resulted in the formation of 6-(4-methoxyphe-
nyl)-9-(4-methoxyphenylmethylene)-1,7,8,9-tetrahydro-cyclopenta[5,6]pyrido[2,3-d][1,2,4]-
triazolo-[4,3-a]pyrimidin-5(H)-ones (4a,b). On the other hand, heating of compound 2c
with acetic acid for 3 hours only yielded 2-acetylhydrazino derivative 3, which on fur-
ther long heating with acetic acid gave 4b. Moreover, alkylation of 4a,b in ethanolic so-
dium ethoxide solution with methyl iodide afforded 1-methyl-6-(4-methoxyphenyl)-9-
-(4-methoxyphenylmethylene)-8,9-dihydrocyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]
pyrimidin-5(H)-ones (5a,b) as shown in Scheme 2. All the synthesized compounds were
characterized by their physical, chemical and spectral data (Tables I–III). IR spectra of
compounds 4a,b showed the presence of characteristic absorption peaks around 3385–3400
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2.05 (br, 2H, NH2), 2.71–2.75 (m, 2H, CH2), 2.84–2.95 (t,
2H, CH2), 5.15 (br, NH), 7.07–7.11 (m, 2H, Ar-H),
7.32–7.39 (m, 3H, Ar-H), 7.45–7.59 (m, 5H, Ar-H) and







2.10 (br, 2H, NH2), 2.73–2.76 (m, 2H, CH2), 2.80–2.92 (m,
2H, CH2), 3.80 (br, NH), 6.98–7.05 (d, 2H, J = 8.43 Hz,
Ar-H), 7.10–7.19 (d, 2H, J = 8,42 Hz, Ar-H), 7.43–7.50 (d,
2H, J = 8.40 Hz, Ar-H), 7.54–7.60 (d, 2H, J = 8.40 Hz,







2.00 (br, 2H, NH2), 2.70–2.72 (m, 2H, CH2), 2.80–2.90 (m,
2H, CH2), 3.80, 3.83 (2s, 6H, 2OCH3), 5.15 (br, NH),
6.92–6.98 (d, 2H, J = 8.41 Hz, Ar-H), 7.00–7.19 (d, 2H, J
= 8.41 Hz, Ar-H), 7.50–7.53 (d, 2H, J = 8.39 Hz, Ar-H),
7.56–7.61 (d, 2H, J = 8.40 Hz, Ar-H), 8.16 (s, 1H, CH),








2.73–2.78 (m, 2H, CH2), 2.82–2.91 (m, 2H, CH2), 2.86 (s,
3H, CH3), 3.82, 3.86 (2s, 6H, 2OCH3), 6.96 (d, 2H, J =
8.39 Hz, Ar-H), 7.11 (d, 2H, J = 8.40 Hz, Ar-H), 7.49 (d,
2H, J = 8.39 Hz, Ar-H), 7.60 (d, 2H, J = 8.40 Hz, Ar-H),







2.72–2.76 (m, 2H, CH2), 2.85–2.91 (m, 2H, CH2), 3.83,
3.89 (2s, 6H, 2OCH3), 6.98–7.04 (d, 2H, Ar-H), 7.08–7.15
(d, 2H, Ar-H), 7.45–7.50 (d, 2H, Ar-H), 7.56–7.63 (d, 2H,
Ar-H), 8.12 (s, 1H, CH), 8.54 (s, 1H, triazole proton) 9.50






2.25 (s, 3H, CH3), 2.71–2.77 (m, 2H, CH2), 2.85–2.91 (m,
2H, CH2), 3.86, 3.91 (2s, 6H, 2OCH3), 7.04 (d, 2H, J =
8.39 Hz, Ar-H), 7.15 (d, 2H, J = 8.38 Hz, Ar-H), 7.47 (d,
2H, J = 8.38 Hz, Ar-H), 7.59 (d, 2H, J = 8.38 Hz, Ar-H),
8.08 (s, 1H, CH), 10.20 (br, NH, D2O exchangeable)
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2.74–2.78 (m, 2H, CH2), 2.84–2.90 (m, 2H, CH2), 3.85,
3.88 (2s, 6H, 2OCH3), 5.54 (br, NH2), 6.99 (d, 2H, J =
8.38 Hz, Ar-H), 7.10 (d, 2H, J = 8.39 Hz, Ar-H), 7.49 (d,
2H, J = 8.40 Hz, Ar-H), 7.61 (d, 2H, J = 8.40 Hz, Ar-H),
8.22 (s, 1H, CH), 10.50 (br, NH) (NH, NH2 D2O ex-
changeable)
4d 3410 (br, NH),
1698 (CO),
1615 (C=N)
2.73–2.82 (m, 2H, CH2), 2.84–2.92 (m, 2H, CH2), 3.85,
3.90 (2s, 6H, 2OCH3), 6.95–6.99 (d, 2H, Ar-H), 7.03–7.15
(m, 2H, Ar-H), 7.18–7.21 (d, 2H, Ar-H), 7.33–7.43 (m,
3H, Ar-H), 7.54–7.58 (d, 2H, Ar-H), 7.60–7.64 (d, 2H,
Ar-H), 8.20 (s, 1H, CH), 10.70 (br, NH, D2O exchange-
able)
4e 3420 (br, NH),
1695 (CO),
1595 (C=N)
2.72–2.78 (m, 2H, CH2), 2.81–2.89 (m, 2H, CH2), 3.84,
3.89 (2s, 6H, 2OCH3), 6.94–7.00 (d, 2H, Ar-H), 7.03–7.12
(d, 2H, Ar-H), 7.16–7.22 (d, 2H, Ar-H), 7.38–7.42 (d, 2H,
Ar-H), 7.50–7.58 (d, 2H, Ar-H), 7.62–7.67 (d, 2H, Ar-H),
8.14 (s, 1H, CH), 11.00 (br, NH, D2O exchangeable)
4f 3400 (br, NH),
1700 (CO),
1640 (C=N)
2.74–2.80 (m, 2H, CH2), 2.83–2.90 (m, 2H, CH2), 3.82,
3.85, 3.89 (3s, 9H, 3OCH3), 6.90–6.96 (d, 2H, Ar-H),
7.01–7.11 (d, 2H, Ar-H), 7.15–7.20 (d, 2H, Ar-H),
7.36–7.40 (d, 2H, Ar-H), 7.52–7.57 (d, 2H, Ar-H),







2.74–2.78 (m, 2H, CH2), 2.86–2.94 (m, 2H, CH2), 3.49 (s,
3H, N-CH3), 3.84, 3.90 (2s, 6H, 2OCH3), 7.00 (d, 2H, J =
8.38 Hz, Ar-H), 7.12 (d, 2H, J = 8.42 Hz, Ar-H), 7.47 (d,
2H, J = 8.39 Hz, Ar-H), 7.58 (d, 2H, J = 8.41 Hz, Ar-H),





2.23 (s, 3H, CH3), 2.73–2.79 (m, 2H, CH2), 2.83–2.90 (m,
2H, CH2), 3.67 (s, 3H, N-CH3), 3.88, 3.93 (2s, 6H,
2OCH3), 7.07 (d, 2H, J = 8.37 Hz, Ar-H), 7.14 (d, 2H, J =
8.38 Hz, Ar-H), 7.48 (d, 2H, J = 8.40 Hz, Ar-H), 7.63 (d,
2H, J = 8.40 Hz, Ar-H), 8.13 (s, 1H, CH)
6a 3405 (br, NH),
1685 (CO),
1610 (C=N)
2.35 (s, 3H, CH3), 2.74–2.78 (m, 2H, CH2), 2.84–2.91 (m,
2H, CH2), 3.86, 3.90 (2s, 6H, 2OCH3), 5.50 (br, NH2, D2O
exchangeable), 7.01 (d, 2H, J = 8.41 Hz, Ar-H), 7.14 (d,
2H, J = 8.40 Hz, Ar-H), 7.48 (d, 2H, J = 8.39 Hz, Ar-H),
7.61 (d, 2H, J = 8.40 Hz, Ar-H), 8.13 (s, 1H, imidazole






2.72–2.76 (m, 2H, CH2), 2.85–2.90 (m, 2H, CH2), 3.87,
3.91 (2s, 6H, 2OCH3), 5.62 (br, NH2, D2O exchangeable),
6.96–7.05 (m, 4H, Ar-H), 7.15 (d, 2H, J = 8.42 Hz, Ar-H),
7.34–7.43 (m, 3H, Ar-H), 7.50 (d, 2H, J = 8.41 Hz, Ar-H),
7.62 (d, 2H, J = 8.39 Hz, Ar-H), 8.09 (s, 1H, imidazole






2.75–2.81 (m, 2H, CH2), 2.87–2.94 (m, 2H, CH2), 3.88,
3.93 (2s, 6H, 2OCH3), 7.02 (d, 2H, J = 8.39, Hz, Ar-H),
7.13–7.20 (m, 4H, Ar-H), 7.30–7.38 (m, 3H, Ar-H), 7.48
(d, 2H, J = 8.38 Hz, Ar-H), 7.62 (d, 2H, J = 8.40 Hz,
Ar-H), 8.19 (s, 1H, CH), 8.30 (s, 1H, azomethine proton),
9.00, 10.80 (br, 2H, 2NH, D2O exchangeable)
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2.71–2.77 (m, 2H, CH2), 2.80–2.86 (m, 2H, CH2), 3.83,
3.88 (2s, 6H, 2OCH3), 6.97 (d, 2H, J = 8.37 Hz, Ar-H),
7.08 (d, 2H, J = 8.38 Hz, Ar-H), 7.26 (d, 2H, J = 8.40 Hz,
Ar-H), 7.51 (d, 2H, J = 8.41 Hz, Ar-H), 7.59 (d, 2H, J =
8.42 Hz, Ar-H), 7.69 (d, 2H, J = 8.40 Hz, Ar-H), 8.06 (s,
1H, azomethine proton), 8.17 (s, 1H, CH), 9.70, 11.00
(2brs, 2NH, D2O exchangeable)
7c 3375 (brs, NH),
1676 (CO),
1605 (C=N)
2.69–2.76 (m, 2H, CH2), 2.83–2.89 (m, 2H, CH2), 3.79,
3.86, 3.91 (3s, 9H, 3OCH3), 7.09–7.10 (d, 2H, Ar-H),
7.13–7.17 (d, 2H, Ar-H), 7.34–7.40 (d, 2H, Ar-H),
7.43–7.49 (d, 2H, Ar-H), 7.52–7.57 (d, 2H, Ar-H),
7.65–7.70 (d, 2H, Ar-H), 8.05 (s,1H, azomethine proton),









2.71–2.78 (m, 2H, CH2), 2.82–2.90 (m, 2H, CH2), 3.86,
3.90 (2s, 6H, 2OCH3), 6.93–6.98 (d, 2H, Ar-H), 7.11–7.17
(d, 2H, Ar-H), 7.37–7.42 (d, 2H, Ar-H), 7.56–7.60 (d, 2H,







2.75–2.82 (m, 2H, CH2), 2.84–2.93 (m, 2H, CH2), 3.86,
3.89 (2s, 6H, 2OCH3), 7.03–7.10 (d, 2H, Ar-H), 7.16–7.22
(d, 2H, Ar-H), 7.38–7.42 (d, 2H, Ar-H), 7.58–7.64 (d, 2H,
Ar-H), 8.23 (s, 1H, CH), 8.56 (br, 2H, NH2), 11.30 (br,







2.74–2.82 (m, 2H, CH2), 2.86–2.93 (m, 2H, CH2), 3.55 (br,
1H, OH coupled with H2O of DMSO), 3.85, 3.90 (2s, 6H,
2OCH3), 5.67 (br, NH2, D2O exchangeable), 6.68 (s, 1H,
pyrazole proton), 7.00 (d, 2H, J = 8.41 Hz, Ar-H), 7.26
(d, 2H, J = 8.40 Hz, Ar-H), 7.34 (d, 2H, J = 8.40 Hz,
Ar-H), 7.53 (d, 2H, J = 8.40 Hz, Ar-H), 8.14 (s, 1H, CH),






2.21 (s, 3H, CH3), 2.68–2.73 (m, 2H, CH2), 2.86 (s, 3H,
CH3), 2.89–2.96 (m, 2H, CH2), 3.85, 3.89 (2s, 6H,
2OCH3), 6.25 (s, 1H, pyrazole proton), 7.11 (d, 2H, J =
8.38 Hz, Ar-H), 7.31 (d, 2H, J = 8.39 Hz, Ar-H), 7.45 (d,
2H, J = 8.40 Hz, Ar-H), 7.64 (d, 2H, J = 8.40 Hz, Ar-H),








2.19 (s, 3H, CH3), 2.67–2.74 (m, 2H, CH2), 2.87 (s, 3H,
CH3), 2.90–2.97 (m, 2H, CH2), 3.86, 3.90 (2s, 6H,
2OCH3), 7.12 (d, 2H, J = 8.39 Hz, Ar-H), 7.33 (d, 2H, J =
8.39 Hz, Ar-H), 7.47 (d, 2H, J = 8.41 Hz, Ar-H), 7.65 (d,








1.24–1.31 (t, 3H, CH3), 2.15 (s, 3H, CH3), 2.71–2.78 (m,
2H, CH2), 2.85–2.92 (m, 2H, CH2), 3.42 (s, 2H, CH2),
3.84, 3.86 (2s, 6H, 2OCH3), 4.00–4.10 (q, 2H, CH2), 7.01
(d, 2H, J = 8.39 Hz, Ar-H), 7.13 (d, 2H, J = 8.40 Hz,
Ar-H), 7.45 (d, 2H, J = 8.39 Hz, Ar-H), 7. 62 (d, 2H, J =
8.41 Hz, Ar-H), 8.17 (s, 1H, CH), 9.40, 11.00 (2br, 2NH,
D2O exchangeable)
cm–1 (N-H stretching). Also, 1H NMR spectra of compounds 4a,b showed broad bands
at d 9.50 and 10.20 ppm, while IR and NMR spectra of compound 5a,b revealed the ab-
sence of NH absorption peaks (Table II).
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2.03 (s, 3H, CH3), 2.78–2.83 (m, 2H, CH2), 2.86–2.92 (m,
2H, CH2), 3.87, 3.92 (2s, 6H, 2OCH3), 4.31 (s, 2H, CH2),
7.06 (d, 2H, J = 8.36 Hz, Ar-H), 7.35 (d, 2H, J = 8.38 Hz,
Ar-H), 7.45 (d, 2H, J = 8.39 Hz, Ar-H), 7.70 (d, 2H, J =








2.79–2.85 (m, 2H, CH2), 2.88–2.93 (m, 2H, CH2), 3.88,
3.93 (2s, 6H, 2OCH3), 7.07 (d, 2H, J = 8.38 Hz, Ar-H),
7.38 (d, 2H, J = 8.39 Hz, Ar-H), 7.48 (d, 2H, J = 8.41 Hz,
Ar-H), 7.68 (d, 2H, J = 8.42 Hz, Ar-H), 8.16 (s, 1H, CH),




































































a: R = H b: R = CH3
c: R = NH2 d: Ar' = C H6 5
e: Ar' = 4-ClC H6 4 f: Ar' = 4-OCH C H3 6 4
6a,b
a: Ar' = C H6 5
b: Ar' = 4-ClC H6 4
c: Ar' = 4-OCH C H3 6
a: R = b: R = C HCH3 6 5
Ar'CHO
AcOH
Ar = 4-OCH C H3 6 4
5a,b








Also, the 2-hydrazino- derivative 2c reacted with potassium thiocyanate in boiling
acetic acid to give 3-amino-6-(4-methoxyphenyl)-9-(4-methoxyphenylmethylene)-1,7,8,
9-tetrahydro-cyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (4c). Be-
side correct values in elemental analyses, the spectral data of 4c are in agreement with
the assigned structure (Scheme 2). When compound 2c was heated under reflux with
-haloketones, namely, chloroacetone or 2-bromoacetophenone in dry xylene, it yielded
the respective 1-amino-6-aryl-9-arylidene-1H,5H-imidazo[1’,2’-a]cyclopenta[5,6]pyrido-
-[2,3-d]pyrimidin-5-one (6a,b). The 1H NMR spectrum of 6a, for example, showed that
singlet signals at 2.35 ppm supported the methyl protons, two signals around 2.74–2.91
ppm corresponded to the two methylene groups, two singlets around 3.85–3.90 ppm due
to the two methoxy groups and the broad absorption signal (D2O exchangeable) sup-
ported the amino group. In addition to the pyrazole proton at 8.13 ppm, the spectrum
showed four doublet signals due to the p-substituted phenyl groups with the coupling
constant around 8.40 Hz and the methylenic proton at 8.21 ppm. Also, the 13C NMR sho-
wed that, in addition to the methyl group (18.39 ppm), two methylene groups (27.21 and
27.90 ppm), two methoxy groups (54.97 and 55.33 ppm) and carbonyl groups (163.8 ppm),
eighteen lines around 111.0–158.5 ppm corresponding to 22 sp2 carbon atoms were obta-
ined (Table III).
Further, compound 2c gave the 2-arylmethylene hydrazone derivatives 7a-c when
treated with the appropriate aldehyde in boiling glacial acetic acid. The latter compounds
were cyclized when gently heated in a mixture of bromine and sodium acetate in acetic
acid to afford 3-aryltriazolo[4’,3’:1,2]cyclopentenopyrido[2,3-d]pyrimidines (4d-f). Beside
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Table III. 13C NMR of some new compounds
Compd.
No.
13C NMR (d, ppm)
(DMSO-d6)
2c 27.01, 27.95 (2C, 2CH2), 54.98, 55.17, (2C, 2OCH3), 108.5, 112.9, 113.1, 114.2, 124.4,
128.9, 129.5, 130.6, 130.7, 130.8, 132.9, 138.9, 148.2, 154.7, 158.3, 158.8 (16 line for 20
sp2 carbon atoms) and 163.9 (CO)
4a 27.12, 27.93 (2C, 2CH2), 54.95, 55.21, (2C, 2OCH3), 110.2, 112.9, 113.8, 118.5, 125.4,
127.3, 129.1, 131.7, 132.3, 133.8, 134.9, 137.6, 147.5, 153.4, 155.3, 157.2, 158.3 (17 line
for 21 sp2 carbon atoms) and 165.2 (CO)
4c 13C-NMR: 27.11, 27.96 (2C, 2CH2), 54.96, 55.18, (2C, 2OCH3), 110.4, 112.3, 113.6, 118.2,
124.5, 127.9, 128.4, 129.3, 130.7, 130.2, 131.8, 134.9, 138.5, 148.1, 154.4, 158.2, 158.8 (17
line for 21 sp2 carbon atoms) and 163.5 (CO)
4f 27.11, 27.94 (2C, 2CH2), 54.96, 55.15, 56.23 (3C, 3OCH3), 108.3, 112.5, 113.5, 114.7,
124.7, 128.6, 129.5, 130.9, 131.2, 131.8, 132.3, 132.7, 134.8, 138.9, 140.2, 144.6, 148.2,
154.7, 167.0, 158.3, 158.8 (21 line for 27 sp2 carbon atoms) and 163.9 (CO)
6a 18.39 (CH3), 27.21, 27.90 (2C, 2CH2), 54.97, 55.33, (2C, 2OCH3), 111.0, 112.7, 114.2,
118.6, 125.7, 127.7, 128.5, 129.5, 131.3, 132.5, 133.8, 135.6, 137.8, 147.4, 152.9, 154.3,
157.4, 158.5 (18 line for 22 sp2 carbon atoms) and 163.8 (CO)
13 24.31, 26.58 (2 CH2), 109.3, 127.0, 127.5, 127.6, 127.7, 127.8, 129.2, 129.4, 130.9, 132.1,
133.1, 136.6, 138.7, 150.5, 153.7, 158.4 (16 line for 20 sp2 carbon atoms), 163.8 (CO)
and 174.2 (C=S)
correct values in elemental analysis, the spectral data of 7a-c and 4d-f are in agreement
with the assigned structures. The 1H NMR spectra revealed the absence of azomethine
protons. Also, the formation of triazolopyridopyrimidine 4d-f from 7a-c may be accom-
plished via brominating the methylenic proton or N-3 of the pyrimidine ring followed
by elimination of hydrogen bromide, as shown in Scheme 3.
Treatment of compound 2c with nitrous acid led to the formation of 6-(4-methoxy-
phenyl)-9-(4-methoxyphenylmethylene)-1,7,8,9-tetrahydrocyclopenta[5,6]-pyrido[2,3-d][1,
2,3,4]tetrazolo[4,5-a]pyrimidin-5(H)-one (8) (Scheme 4). The IR spectrum of 8 displayed
absorption bands at 3240 cm–1 (NH) and 1702 cm–1 (CO). The latter compound was re-
duced to 2-amino-5-(4-methoxyphenyl)-8-(4-methoxyphenyl-methylene)-7,8-dihydro-
-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidine-4(H)-one (9) by zinc dust and acetic acid.
5-(4-Methoxyphenyl)-8-(4-methoxyphenylmethylene)-2-hydrazino-7,8-dihydro-6H-cyclopenta
[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (2c) reacted with b-cyano-ester, b-diketones and b-ke-
toesters to form 2-(1-pyrazolyl) derivatives. Thus, heating compound 2c with ethylcyano-
acetate, pentane-2,4-dione and/or 3-chloropentane-2,4-dione, yielded the respective 2-
-(3,5-substituted-4-(un)substituted-pyrazol-1-yl)-5-(4-methoxyphenyl)-8-(4-methoxy-
-phenyl-methylene)-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-ones
10a-c, respectively (Scheme 5).
Compound 2c condensed with ethyl acetoacetate upon heating in boiling ethanol to
afford 2-[ethyl-5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-7,8-dihydro-6H-cy-
clopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one]acetatehydrazone (11), which could be cy-
clized either by prolonged heating in ethanol or by heating in sodium ethoxide solution
to give 5-(4-methoxyphenyl)-8-(4-methoxyphenylmethylene)-2-(3-methyl-4H-pyrazol-5-
-one-1-yl)-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (12).
Finally, heating 2c with carbon disulphide in ethanolic potassium hydroxide solu-
tion gave 3-thioxo-6-(4-methoxyphenyl)-9-(methoxyphenylmethylene)-1,2,8,9-tetrahydro-
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Table IV. Percent inflammatory activity of the tested compounds




3 hours 4 hours Potency
2a 27.29 ± 2.64 28.27 ± 2.75b 0.34
2b 56.82 ± 2.53 56.81 ± 2.16b 0.71
2c 52.28 ± 2.18 54.55 ± 2.62b 0.67
4a 27.28 ± 2.73 29.54 ± 2.79b 0.37
4c 75.01 ± 2.52 77.26 ± 1.92b 0.98
6a 63.70 ± 1.93 63.62 ± 1.92 0.80
9 75.00 ± 2.79 79.53 ± 3.72 1.00
10a 76.08 ± 2.67 82.79 ± 2.18 1.03
10b 31.80 ± 3.45 31.80 ± 3.69b 0.39
11 15.90 ± 2.73 19.04 ± 2.24 0.24
12 52.27 ± 2.80 52.27 ± 2.79b 0.65
13 56.81 ± 1.94 59.09 ± 2.74b 0.74
Control – – –
Ibuprofen 75.00 ± 2.53 79.54 ± 2.25 1.00
Dose: 30 mg kg–1 b.m. of the tested compound and standard drug.
a Mean ± SEM (n = 6).
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-7H-cyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (13) (Scheme 5).
The IR spectrum of 13 displayed absorption bands at 3465–3400 cm–1 (2NH) and 1686
cm–1 (CO). The 13C NMR spectrum (DMSO-d6) of 13 showed two signals due to the sp3
carbon atoms, sixteen lines assigned to 20 sp2 carbon atoms and, in addition to the sig-
nal for the carbonyl group, the spectrum showed a strong peak corresponding to C=S at
174.2 ppm.
The pharmacological screening of the tested compounds showed anti-inflammatory
activity ranging from 19.0 to 82.8% (Table IV), whereas the standard drug ibuprofen
showed 79.5% inhibition after 4 h. The anti-inflammatory activity of 2-pyrazolyl-pyri-
dopyrimidine derivatives 10a, 10b and 12 ranged from 31.8 to 82.8%. The aminopyra-
zolyl derivative 10a with hydroxyl and amino groups showed higher activity than the
standard drug ibuprofen, whereas when these groups were replaced by a methyl group,
the anti-inflammatory activity decreased. Also, it was observed that the triazolopyrido-
-pyrimidine derivatives 4a, 4c and 13 showed activity ranging from 29.5 to 77.3%, and
3-aminotriazolopyridopyrimidine 4c showed activity nearly equivalent to the standard
drug. 2-Aminopyrido[2,3-d]pyrimidine (9) showed activity (79.5%) equivalent to that of
ibuprofen. Other tested compounds showed moderate anti-inflammatory activity. It is
clear from Table IV that the presence of amino group in triazolo-/or pyrazolo-pyrido-
pyrimidine increases the anti-inflammatory activity.
Compounds 4c, 6a, 9 and 10a which showed anti-inflammatory activity comparable
or equal to that of the standard were further tested for their analgesic activity at a dose
of 30 mg kg–1 ibuprofen (Table V). Compounds showed analgesic activity ranging from
58.4 to 72.7%, whereas the standard drug ibuprofen showed 69.5% inhibition. Compounds
4c, 9 and 10a showed the highest anti-inflammatory activity, 72.7, 59.3 and 70.2%, resp.
The remaining compounds showed reduced analgesic activity. These compounds were
further screened for their acute ulcerogenic activity. The tested compounds showed sig-
nificant reduction in ulcerogenic activity ranging from 0.7 ± 0.15 to 1.06 ± 0.17, whereas
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4c 1.40 ± 0.150 2.42 ± 0117b 72.7 1.04 1.064 ± 0.17c
6a 1.34 ± 0.137 2.13 ± 0145b 58.4 0.84 0.670 ± 0.21c
9 1.34 ± 0.136 2.12 ± 0.146b 59.3 0.85 0.732 ± 0.18c
10a 1.41 ± 0.150 1.86 ± 0.094b 70.2 1.02 0.667 ± 0.15c
13 1.80 ± 0.188 2.35 ± 0.180b 31.2 1.02 0.668 ± 0.22c
Ibuprofen 1.15 ± 0.060 1.95 ± 0.097 69.5 1.00 1.665 ± 0.25
Control – – –
Dose: 30 mg kg–1 b.m. of the tested compound and standard drug.
a Mean ± SEM (n = 6).
b Significant difference relative to ibuprofen: p < 0.0001.
c Significant difference from ibuprofen: p < 0.05.
the standard drug ibuprofen showed a severity index of 1.66 ± 0.25. Maximum reduction
in ulcerogenic activity was found for compound 10a having the hydroxyl and amino
groups of 2-pyrazolo-pyridopyrimidine ring (0.66 ± 0.15). The rest of the compounds
also showed a better gastro interact safety profile than ibuprofen.
CONCLUSIONS
The present investigation offers new, rapid and effective procedures for the synthe-




(H)-one (6a) and 2-amino-5-(4-methoxy-phenyl)-8-(4-methoxyphenyl-methylene)-7,8-di-
hydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (9) exhibited a potent anti-in-
flammatory activity whereas 2-(3-amino-5-hydroxypyrazol-1-yl)-pyrido[2,3-d]pyrimi-
din-4-one derivative 10a was the most active.
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S A @ E T A K
Sinteza i vrednovanje analgetskog, protuupalnog i ulcerogenog
djelovanja nekih triazolo- i 2-pirazolil-pirido[2,3-d]-pirimidina
HEND N. HAFEZ, HEBAT-ALLAH S. ABBAS i ABDEL-RAHMAN B. A. EL-GAZZAR
U radu je opisana sinteza serije 2-hidrazino-7,8-dihidro-6H-ciklopenta[5,6]pirido[2,
3-d]pirimidina i njihovih 1,7,8,9-tetrahidrociklopenta[5,6]pirido[2,3-d][1,2,4]triazolo[4,3-
-a]pirimidinskih, 1,7,8,9-tetrahidrociklopenta[5,6]pirido[2,3-d][1,2,3,4]tetrazolo[4,5-a]pirimi-
dinskih, 8,9-dihidro-7H-ciklopenta[5,6]pirido[2,3-d]imidazolo[1,2-a]pirimidinskih i 2-
-(pirazol-1-il)-7,8-dihidro-6H-ciklopenta[5,6]pirido[2,3-d]pirimidinskih derivata s po-
tencijalnim protuupalnim i analgetskim te manjim ulcerogenim djelovanjem. Spojevima
s izra`enim protuupalnim djelovanjem testirano je analgetsko i ulcerogeno djelovanje.
Spojevi 3-amino-6-(4-aril)-9-(4-arilmetilen)-ciklopenta[5,6]pirido[2,3-d][1,2,4]triazolo[4,3-a]
pirimidin-5(H)-on (4c), 1-amino-2-metil-6-(4-aril)-9-(4-aril-metilen)-ciklopenta[5,6]pirido
[2, 3-d]imidazolo[1,2-a]pirimidin-5(H)-on (6a), 2-amino-5-(4-aril)-8-(4-arilmetilen)-ciklo-
penta[5,6]pirido[2,3-d]pirimidin-4(H)-on (9), 2-(3-amino-5-hidroksipirazol-1-il)-5-(4-aril)-8-
-(4-arilmetilen)-ciklopenta[5,6]-pirido[2,3-d]pirimidin-4(H)-on (10a) i 3-tiokso-6-(4-aril)-9-(4-
-arilmetilen)-ciklopenta[5,6]pirido[2,3-d][1,2,4]triazolo[4,3-a]pirimidin-5(H)-on (13) poka-
zali su zna~ajno analgetsko djelovanje. Spoj 2-(3-amino-5-hidroksipirazol-1-il)-5-(4-aril)-8-
-(4-arilmetilen)-ciklopenta[5,6]pirido[2,3-d]pirimidin-4(H)-on (10a) je vode}i spoj s ja~im
protuupalnim djelovanjem (82,8%) od ibuprofena (79,5%), a slabijim ulcerogenim djelo-
vanjem.
Klju~ne rije~i: pirido[2,3-d]pirimidini, [1,2,4]triazol anelacija, protuupalno djelovanje, analgetsko dje-
lovanje
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